Therapy Overview & Search
This is the search page for all therapy, you can search for name or condition
Filter By
Therapeutic Area
Manufacturer
SORT BY
-
Abrilada (adalimumab-afzb)
Abrilada (adalimumab-afzb) is an FDA-approved, citrate-free, interchangeable biosimilar to Humira. Like Humira, Abrilada is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.Manufacturer:PfizerRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-844-722-6672Approved Indication:
-
- reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
- reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
- reducing signs and symptoms in adult patients with active ankylosing spondylitis
- treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
- treatment of moderately to severely active ulcerative colitis in adult patients
- treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
- treatment of moderate to severe hidradenitis suppurativa in adult patients
- treatment of non-infectious intermediate, posterior, and panuveitis in adult patients
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
- Uveitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
-
Adakveo (crizanlizumab-tmca)
Adakveo (crizlanizumab-tmca) is a monoclonal antibody given by infusion to patients with sickle cell disease to decrease the number of vasoocclusive crises.Manufacturer:NovartisRoute of Administration:IntravenousSite of Care:OutpatientWebsite:phone:1-800-282-7630Approved Indication:
to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease
Conditions:
- Sickle Cell Disease1
-
Adcirca (tadalafil)
Adcirca (tadalafil) is an inhibitor of the enzyme phosphodiesterase type-5 approved to treat certain types of pulmonary hypertension. By relaxing muscles and the vasculature in the lungs, it increases blood flow and can help improve exercise tolerance.Manufacturer:United TherapeuticsRoute of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability
Conditions:
- Pulmonary Arterial Hypertension
-
Adempas (riociguat)
Adempas (riociguat) is a soluble guanylate cyclose stimulator approved to treat adults with WHO group 1 pulmonary arterial hypertension or WHO group 4 chronic thromboembolic pulmonary hypertension (CTEPH). Adempas is the only medication FDA-approved for the treatment of CTEPH.Manufacturer:BayerRoute of Administration:OralSite of Care:OutpatientWebsite:phone:1-855-423-3672Approved Indication:
- persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and functional class
- pulmonary arterial hypertension (WHO group 1) to improve exercise capacity, improve functional class, and delay clinical worsening
Conditions:
- Chronic Thromboembolic Pulmonary Hypertension
- Pulmonary Arterial Hypertension
-
Alvaiz (eltrombopag choline)
Alvaiz (eltrombopag choline) is a TPO-receptor agonist approved to increase platelet production in patients with immune thrombocytopenia, aplastic anemia, or hepatitis C to facilitate the use of other medications.Manufacturer:TevaRoute of Administration:OralSite of Care:OutpatientWebsite:phone:844-248-7949Approved Indication:
- treatment of thrombocytopenia in adult and pediatric patients 6 years and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy and who are at an increased risk for bleeding
- treatment of thrombocytopenia in adult patients with chronic hepatitis C to allow the initiation of interferon-based therapy
- treatment of adult patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy
Conditions:
- Immune Thrombocytopenia
- Aplastic Anemia
Therapeutic Area:
- Oncology
-
Alyq (tadalafil)
Alyq (tadalafil) is the authorized generic for Adcirca. Like Adcirca, Alyq is an inhibitor of the enzyme phosphodiesterase type-5 approved to treat certain types of pulmonary hypertension. By relaxing muscles and the vasculature in the lungs, it increases blood flow and can help improve exercise tolerance.Approved Indication:
treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability
Conditions:
- Pulmonary Arterial Hypertension
-
ambrisentan
Ambrisentan is an endothelin receptor antagonist approved to treat adults with WHO group 1 pulmonary arterial hypertension. By increasing pulmonary vasodilation, it can improve exercise tolerance and quality of life.Manufacturer:GileadRoute of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
To improve exercise ability and delay clinical worsening in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening WHO group 1 pulmonary arterial hypertension
Conditions:
- Pulmonary Arterial Hypertension
-
Amitiza (lubiprostone)
(Amitiza) lubiprostone is a secretagogue approved by the FDA to increase the amount of water in the intestines to improve constipation and decrease abdominal pain. Amitiza must be taken with food.Manufacturer:MiscRoute of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- treatment of irritable bowel syndrome with constipation in women 18 years of age and older
- treatment of chronic idiopathic constipation in adults
- treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not required frequent opioid dose escalation
Conditions:
- Irritable Bowel Syndrome with Constipation (IBS-C)
- Chronic Idiopathic Constipation (CIC)
- Opioid-Induced Constipation (OIC)
Therapeutic Area:
- Gastroenterology
-
Amjevita (adalimumab-atto)
Amjevita (adalimumab-atto) is the first FDA-approved biosimilar to Humira. Like Humira, Amjevita is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.Manufacturer:AmgenRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-888-826-5384Approved Indication:
-
- reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
- reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
- reducing signs and symptoms in adult patients with active ankylosing spondylitis
- reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderate to severely active Crohn’s Disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab
- inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine, or 6-mercaptopurine
- treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Juvenile Idiopathic Arthritis
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
-
Aranesp (darbepoetin alfa)
Aranesp (darbepoetin alfa) mimics endogenous erythropoietin to increase the production of red blood cells in patients with anemia due to chronic kidney disease or certain chemotherapy treatments.Manufacturer:AmgenRoute of Administration:Subcutaneous, IntravenousSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- treatment of anemia due to chronic kidney disease in patients on dialysis and patients not on dialysis
- treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy in patients who cannot be managed by transfusion, who do not require immediate correction of anemia, and who are NOT receiving biologic products, hormonal agents, or radiotherapy without concomitant myelosuppressive chemotherapy
Conditions:
- Chronic Kidney Disease
- Anemia of Chronic Kidney Disease
- Chemotherapy-Induced Anemia
Therapeutic Area:
- Oncology
-
Avsola (infliximab-axxq)
Avsola (infliximab-axxq) is an FDA-approved biosimilar to Remicade. Like Remicade, Avsola is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.Manufacturer:AmgenRoute of Administration:IntravenousSite of Care:OutpatientWebsite:phone:866-264-2778Approved Indication:
-
- reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy
- reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease
- reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
- [in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signa and symptoms in adult patients with active ankylosing spondylitis
- reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients
- treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
-
Bonsity (teriparatide)
Bonsity (teriparatide) is a synthetic form of the natural human parathyroid hormone. Given by once-daily injection, it increases bone mineral density and strength to reduce the risk of fracture in patients with osteoporosis.Manufacturer:AlvogenRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:833-330-0806Approved Indication:
- treatment of postmeopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to over available osteoporosis therapyy
- increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy
- treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy
Conditions:
- Osteoporosis